Drug Trial Radar · NCT04660812
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
227
Actual
Start
May 10, 2021
Primary completion
Sep 5, 2025
Study completion Sep 5, 2025
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Gilead Sciences
- First posted
- Dec 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
Conditions
- Metastatic Colorectal Cancer
Interventions
AB680Drug
AB680 is a cluster of differentiated CD73 Inhibitor
EtrumadenantDrug
Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist
ZimberelimabDrug
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
BevacizumabDrug
Bevacizumab is administered as part of standard chemotherapy regimen
m-FOLFOX-6 regimenDrug
mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen
RegorafenibDrug
Regorafenib is administered as part of standard chemotherapy regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A and B - Progression-free Survival (PFS)Time frame: From randomization until death from any cause (up to approximately 3-7 years)
- Cohort C - Objective Response Rate (ORR)Time frame: From randomization until death from any cause (up to approximately 3-7 years)
- Number of Participants With Treatment-emergent Adverse EventsTime frame: Up to approximately 10 Months
Locations
44 sites in 6 countries. Site status is shown where the registry gives one.
Arizona Clinical Research Center Inc
Tucson, Arizona
City of Hope Comprehensive Cancer Center
Duarte, California
UCLA Hematology Oncology
Santa Monica, California
Yale Cancer Center
New Haven, Connecticut
Sibley Memorial Hospital
Washington D.C., District of Columbia
Winship Cancer Institute at Emory University
Atlanta, Georgia
Ochsner Medical Center (OMC)
New Orleans, Louisiana
American Oncology Partners of Maryland PA
Bethesda, Maryland
Washington University School of Medicine
St Louis, Missouri
Comprehensive Cancer Centers Of Nevada
Las Vegas, Nevada
NYU Langone Medical Center - NYU Medical Oncology Associates
New York, New York
New York-Presbyterian Hospital-Columbia University Medical Center
New York, New York
Prisma Health-Upstate
Greenville, South Carolina
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Wisconsin School of Medicine
Madison, Wisconsin
Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
Bordeaux, France
Centre Georges Francois Leclerc
Dijon, France
Hopital Hotel Dieu
Nantes, France
Hopital Saint Antoine
Paris, France
Groupe Hospitalier Pitie-Salpetriere-Centre De Recherche et de Medecine de l'Obesite
Paris, France
CHU la Miletrie
Poitiers, France
IRCCS - Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Castellana Grotte, Italy
Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica
Florence, Italy
Azienda Ospedaliera Niguarda Ca' Granda
Milan, Italy
Instituto Europeo di Oncologia
Milan, Italy
Istituto Clinico Humanitas IRCCS
Rozzano, Italy
Universita di Siena - Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte
Siena, Italy
Chonnam National University Hwasun Hospital
Hwasun, South Korea
Seoul National University Bundang Hospital
Seoul, South Korea
Seoul National University Hospital (SNUH)
Seoul, South Korea
Severance Hospital | Yonsei University Health System
Seoul, South Korea
Asan Medical Center | University of Ulsan College of Medicine
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Kyungpook National University Chilgok Hospital
Seoul, South Korea
Hospital Universitario La Paz
Madrid, Spain
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Complejo Hospitalario de Orense
Ourense, Spain
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.